Calypso Biotech S.A. has mAbs against an undisclosed target to treat fistulizing Crohn's disease, a severe form of the condition that usually is refractory to marketed therapies such as immunomodulators. The company expects it will be able to treat the disease's underlying inflammation as well as its fibrotic complications.

Co-founders and co-VPs of R&D Alain Vicari and Yolande Chvatchko worked on the human mAbs, dubbed the CALY-001 program, when they were at Merck KGaA's Merck Serono S.A. unit. The pharma shelved the program for strategic reasons when it decided to close its Geneva headquarters in 2012.